Angela DeMichele

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. doi request reprint Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer
    Angela DeMichele
    Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer Res 69:4184-91. 2009
  2. ncbi request reprint Developing safety criteria for introducing new agents into neoadjuvant trials
    Angela DeMichele
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 19:2817-23. 2013
  3. pmc Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
    Priya P Gor
    Center for Cancer and Hematologic Disease, 1930 E Route 70, Cherry Hill, NJ 08003, USA
    Breast Cancer Res 12:R26. 2010
  4. pmc Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study
    Angela DeMichele
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:4151-9. 2008
  5. ncbi request reprint Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology
    Timothy R Rebbeck
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Cancer Epidemiol Biomarkers Prev 16:444-50. 2007
  6. pmc Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors
    H Irene Su
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA 19146, USA
    Fertil Steril 94:645-54. 2010
  7. ncbi request reprint Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk
    Timothy R Rebbeck
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Cancer Epidemiol Biomarkers Prev 16:1318-20. 2007
  8. pmc Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women
    Timothy R Rebbeck
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Carcinogenesis 30:269-74. 2009
  9. ncbi request reprint Case-control study of postmenopausal hormone replacement therapy and endometrial cancer
    Brian L Strom
    Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, 19104 6021, USA
    Am J Epidemiol 164:775-86. 2006
  10. pmc Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors
    Krupali Desai
    Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street, 2 Gates Building, Philadelphia, PA 19104, USA
    Support Care Cancer 21:43-51. 2013

Collaborators

Detail Information

Publications65

  1. doi request reprint Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer
    Angela DeMichele
    Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer Res 69:4184-91. 2009
    ..Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41)...
  2. ncbi request reprint Developing safety criteria for introducing new agents into neoadjuvant trials
    Angela DeMichele
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 19:2817-23. 2013
    ..These adaptations of phase II design enable acceleration of drug development by reducing time and cost to screen novel therapies for activity without compromising safety...
  3. pmc Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
    Priya P Gor
    Center for Cancer and Hematologic Disease, 1930 E Route 70, Cherry Hill, NJ 08003, USA
    Breast Cancer Res 12:R26. 2010
    ..We hypothesize that functional single nucleotide polymorphisms (SNPs) in drug metabolizing enzymes (DMEs) that activate (CYPs) or metabolize (GSTs) cyclophosphamide account for some of the observed variability in disease outcomes...
  4. pmc Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study
    Angela DeMichele
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 26:4151-9. 2008
    ....
  5. ncbi request reprint Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology
    Timothy R Rebbeck
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Cancer Epidemiol Biomarkers Prev 16:444-50. 2007
    ....
  6. pmc Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors
    H Irene Su
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, PA 19146, USA
    Fertil Steril 94:645-54. 2010
    ..To determine if genetic variation in chemotherapy metabolism are associated with risk of ovarian failure in breast cancer patients after adjuvant chemotherapy...
  7. ncbi request reprint Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk
    Timothy R Rebbeck
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Cancer Epidemiol Biomarkers Prev 16:1318-20. 2007
  8. pmc Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women
    Timothy R Rebbeck
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Carcinogenesis 30:269-74. 2009
    ..We further report that these genes confer their effects in HER2- tumors, interact with one another to confer breast cancer susceptibility in AA women and interact with hormone exposures in AA and EA women...
  9. ncbi request reprint Case-control study of postmenopausal hormone replacement therapy and endometrial cancer
    Brian L Strom
    Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, 19104 6021, USA
    Am J Epidemiol 164:775-86. 2006
    ..Thus, if HRT is to be used in women with an intact uterus, this study confirms the benefit of adding progestins to the regimen...
  10. pmc Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors
    Krupali Desai
    Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street, 2 Gates Building, Philadelphia, PA 19104, USA
    Support Care Cancer 21:43-51. 2013
    ....
  11. pmc Risk factors for lymphedema after breast cancer treatment
    Sandra A Norman
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104 6021, USA
    Cancer Epidemiol Biomarkers Prev 19:2734-46. 2010
    ..As cancer treatments evolve, it is important to reevaluate their effect on lymphedema risk in breast cancer survivors...
  12. ncbi request reprint A retrospective case-control study of the use of hormone-related supplements and association with breast cancer
    Timothy R Rebbeck
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Int J Cancer 120:1523-8. 2007
    ..Additional confirmatory studies are required to determine whether black cohosh could be used to prevent breast cancer...
  13. pmc Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
    Kannie Chim
    Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street 2 Gates, Philadelphia, Pennsylvania 19104, USA
    BMC Cancer 13:401. 2013
    ..Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs...
  14. pmc A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use
    Jun J Mao
    Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, PA, United States Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, PA, United States Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, PA, United States Electronic address
    Eur J Cancer 50:267-76. 2014
    ..Arthralgia is a common and debilitating side-effect experienced by breast cancer patients receiving aromatase inhibitors (AIs) and often results in premature drug discontinuation...
  15. pmc Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors
    Jun J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, 3400 Spruce Street 2 Gates, Philadelphia, PA 19104, USA
    Breast Cancer Res 13:R8. 2011
    ....
  16. ncbi request reprint Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort
    Angela DeMichele
    Department of Biostatistics and Epidemiology, Abramson Cancer Center, PA, USA
    J Clin Oncol 23:5552-9. 2005
    ..Genotypes in drug-metabolizing enzymes, including functional polymorphisms in cytochrome P450 (CYP) and glutathione S-transferases (GST), may predict treatment-related outcomes...
  17. ncbi request reprint Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk
    Timothy R Rebbeck
    Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104 6021, USA
    J Natl Cancer Inst 98:1311-20. 2006
    ..To investigate the mechanism of this association, we evaluated whether risk of endometrial cancer was associated with the genotypes involved in steroid hormone metabolism and the duration of exogenous hormone use...
  18. doi request reprint Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies
    Rebecca M Speck
    Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, 1121A Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Support Care Cancer 21:549-55. 2013
    ..This study examined the experience and coping strategies for taste alteration in female breast cancer patients treated with docetaxel or paclitaxel...
  19. pmc Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy
    David R Busch
    Dept of Physics and Astronomy, University of Pennsylvania, 209 S 33rd St, Philadelphia, PA 19104 USA
    Biomed Opt Express 4:105-21. 2013
    ..Though preliminary, the study shows how to use the malignancy parameter for separating responders from partial-responders and demonstrates the potential utility of the methodology compared to traditional DOT quantification schemes...
  20. pmc Computer aided automatic detection of malignant lesions in diffuse optical mammography
    David R Busch
    Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Med Phys 37:1840-9. 2010
    ..The methodology is tested in a population of 35 biopsy-confirmed malignant lesions...
  21. pmc Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors
    James J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Integr Cancer Ther 8:123-9. 2009
    ..Given the existing evidence for electroacupuncture (EA) for treatment of osteoarthritis in the general population, this study aims to establish the feasibility of studying EA for treating AI-related arthralgia...
  22. pmc Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography
    Regine Choe
    University of Pennsylvania, Department of Physics, 209 S 33rd Street, Philadelphia, Pennsylvania 19104, USA
    J Biomed Opt 14:024020. 2009
    ..90 to 0.99, suggesting good discriminatory power. The data demonstrate that benign and malignant lesions can be distinguished by quantitative three-dimensional DOT...
  23. doi request reprint Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability
    Mously Leblanc
    Department of Physical Medicine and Rehabilitation, University of Pennsylvania Health System, Philadelphia, PA Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA Electronic address
    Arch Phys Med Rehabil 95:493-8. 2014
    ..To validate the QuickDASH as a patient-reported outcome measure for assessing upper extremity disability in breast cancer survivors...
  24. doi request reprint Genomic predictors of outcome and treatment response in breast cancer
    Lara Dunn
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mol Diagn Ther 13:73-90. 2009
    ..Gene signatures have the potential to transform breast cancer treatment as it becomes tailored to each patient's tumor expression profile and significantly improve the outcomes of this disease...
  25. doi request reprint Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer
    Rebecca M Speck
    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
    J Oncol Pract 9:e234-40. 2013
    ..To determine the incidence of dose-limiting (DL) chemotherapy-induced peripheral neuropathy (CIPN) events in clinical practice...
  26. pmc Predictors of yoga use among patients with breast cancer
    Krupali Desai
    Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA 19104
    Explore (NY) 6:359-63. 2010
    ..However, very little is known about the characteristics of breast cancer patients who use yoga; thus, this study seeks to identify the sociodemographic and clinical characteristics of yoga users among this population...
  27. doi request reprint Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients
    Jun J Mao
    Department of Family Medicine and Community Health, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    J Clin Oncol 27:933-8. 2009
    ..This study aims to describe postmenopausal breast cancer survivors' (BCS) perceptions of PCP-related survivorship care...
  28. pmc Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome
    Vandana Gupta Abramson
    Department of Medicine, University of Pennsylvania, PA, USA
    Anticancer Res 30:1279-85. 2010
    ..Our objectives were to determine whether cyclin D1b is expressed in human breast carcinomas and to characterize the relationship of this protein to both cyclin D1a and clinical outcome in breast cancer patients...
  29. pmc Metrics to evaluate treatment summaries and survivorship care plans: a scorecard
    Steven C Palmer
    Department of Psychiatry, University of Pennsylvania, 3400 Spruce St, 1103 Penn Tower, Philadelphia, PA, 19104, USA
    Support Care Cancer 22:1475-83. 2014
    ..This manuscript presents a recently developed tool to allow rating of breast cancer-specific TS/SCPs as a model for assessing concordance with IOM recommendations and facilitating research and clinical fidelity...
  30. pmc Vitamin d deficiency in postmenopausal breast cancer survivors
    Claire F Friedman
    Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    J Womens Health (Larchmt) 21:456-62. 2012
    ..Given the role vitamin D plays in bone metabolism, we examined the prevalence of and risk factors for vitamin D deficiency in a study of postmenopausal BCS on AIs...
  31. doi request reprint CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients
    Andrew J Rech
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Sci Transl Med 4:134ra62. 2012
    ..We conclude that CD25 blockade depletes and selectively reprograms T(regs) in concert with active immune therapy in cancer patients. These results suggest a mechanism to target cancer-associated T(regs) while avoiding autoimmunity...
  32. ncbi request reprint Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients
    Steven C Palmer
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
    Psychosom Med 66:258-64. 2004
    ..We examined the relationships between the experience of trauma, psychological distress, and PTSD among a waiting room sample of patients with breast cancer...
  33. ncbi request reprint Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance
    Susan M Domchek
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer Res 67:10546-55. 2007
    ..These results suggest that hTERT-specific T cells could contribute to the immunosurveillance of breast cancer and suggest novel opportunities for both therapeutic and prophylactic vaccine strategies for cancer...
  34. ncbi request reprint Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients
    Rebecca M Speck
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA
    Support Care Cancer 20:2433-9. 2012
    ..We also examined the variety of taxane-related side effects in women with and without CIPN in order to discriminate the CIPN symptom experience...
  35. pmc Is screening effective in detecting untreated psychiatric disorders among newly diagnosed breast cancer patients?
    Steven C Palmer
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer 118:2735-43. 2012
    ..This study adopts the novel strategy of evaluating the effectiveness of screening after correcting for disorder for which treatment is already being provided...
  36. ncbi request reprint Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors
    Edwin Rock
    Division of Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Nutr 133:3785S-3793S. 2003
    ..However, except for vitamin D and calcium for prevention of bone loss, current clinical evidence supporting use of nutritional agents remains sparse...
  37. ncbi request reprint Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer
    Angela DeMichele
    Department of Medicine Heme Onc, Rowan Breast Center of the Abramson Cancer Center, University of Pennsylvania, 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 63:8051-6. 2003
    ..Additional studies are needed to confirm these results and elucidate the mechanisms responsible for these differences...
  38. doi request reprint Adult cancer survivorship: evolution, research, and planning care
    Linda A Jacobs
    LIVESTRONG Survivorship Center of Excellence Abramson Cancer Center, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania 19104, USA
    CA Cancer J Clin 59:391-410. 2009
    ..Finally, an overview of evolving treatment summary and care plan initiatives is presented...
  39. pmc Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors
    H Irene Su
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer 116:592-9. 2010
    ....
  40. doi request reprint Experiences with weight change in African-American breast cancer survivors
    Chanita Hughes Halbert
    Department of Psychiatry, Abramson Cancer Center, and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Breast J 14:182-7. 2008
    ..It may be important to provide African-American breast cancer survivors with information about the causes and implications of weight change and strategies for weight control after treatment as part of their follow-up care...
  41. ncbi request reprint Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
    Amy S Clark
    Abramson Cancer Center, Philadelphia, Pennsylvania Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania Division of Hematology Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Cancer Med 3:693-701. 2014
    ..However, vitD levels had no impact on tumor response to NACT or short-term prognosis...
  42. ncbi request reprint Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients
    Angela DeMichele
    Division of Hematology Oncology, Department of Medicine, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer 97:2150-9. 2003
    ....
  43. pmc Current approaches to the management of Her2-negative metastatic breast cancer
    Keerthi Gogineni
    Rena Rowan Breast Center, Abramson Cancer Center, University of Pennsylvania, Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Breast Cancer Res 14:205. 2012
    ..Chemotherapy remains the mainstay of treatment in this group, but biologically based clinical trials of new agents are critical to developing a more effective set of therapies for this patient population...
  44. pmc Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors
    Jun J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA, USA
    Cancer 115:3631-9. 2009
    ..The objective of this study was to evaluate the perceived onset, characteristics, and risk factors for AI-related arthralgia (AIA)...
  45. pmc mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells
    Xiaojun Yang
    Ovarian Cancer Research Center and Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Biochem Biophys Res Commun 431:617-22. 2013
    ..This result will contribute to understanding the molecular mechanism of mir-30d in tumorigenesis and developing novel cancer therapy strategy...
  46. doi request reprint The role of lapatinib in the preoperative therapy of breast cancer
    Rebecca L Hirsh
    Division of Hematology Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Curr Oncol Rep 14:44-7. 2012
    ..Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer...
  47. ncbi request reprint Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer
    Sarah Kim
    Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Immunol Invest 38:324-40. 2009
    ..While much remains to be learned about the mechanisms underlying these variants and their impact on tumor behavior, this area holds promise for future development of prognostic profiles and therapeutics exploiting the immune response...
  48. pmc Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms
    Sandra A Norman
    Department of Medicine, Division of Hematology Oncology, Center for Clinical Epidemiologyand Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    J Clin Oncol 27:390-7. 2009
    ..To examine the incidence, degree, time course, treatment, and symptoms of lymphedema in breast cancer survivors...
  49. ncbi request reprint Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
    Brian J Czerniecki
    Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:1842-52. 2007
    ..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer...
  50. doi request reprint Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 18:568-76. 2012
    ....
  51. ncbi request reprint Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI
    Regine Choe
    Department of Physics and Astronomy, University of Pennsylvania, 209 South 33rd Street, Philadelphia, Pennsylvania 19104 6396, USA
    Med Phys 32:1128-39. 2005
    ..A decrease in total hemoglobin concentration contrast between tumor and normal tissue was also observed over time. The results demonstrate the potential of DOT for measuring physiological parameters of breast lesions during chemotherapy...
  52. ncbi request reprint Morbidity and mortality of colorectal carcinoma surgery differs by insurance status
    Rachel Rapaport Kelz
    Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer 101:2187-94. 2004
    ....
  53. doi request reprint The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer
    Stephen M Keefe
    Abramson Cancer Center, University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Curr Oncol Rep 12:22-5. 2010
    ..As yet, combination regimens have failed to demonstrate a survival advantage. Emerging research suggests that single-nucleotide polymorphism in VEGF may predict response to combined therapy...
  54. ncbi request reprint The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy
    Eleanor E R Harris
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Breast J 12:431-6. 2006
    ..15). There was no difference in local recurrence after BCT between HER-2-positive and negative breast cancers at 5 years. Therefore HER-2 overexpression does not appear to be a contraindication to BCT...
  55. pmc Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy
    James V Alvarez
    Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Cell 24:30-44. 2013
    ..Our findings identify Par-4-induced multinucleation as a mechanism of cell death in oncogene-addicted cells and establish Par-4 as a negative regulator of breast cancer recurrence. ..
  56. ncbi request reprint Early bacteremia in pediatric hematopoietic stem cell transplant patients on oral antibiotic prophylaxis
    Leslie S Kersun
    Department of Pediatrics, Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pediatr Blood Cancer 45:162-9. 2005
    ..Our purpose was to determine the incidence of bacteremia and antimicrobial resistance post-HSCT in pediatric patients receiving GD, and to identify risk factors associated with infection...
  57. pmc Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women
    Susan Colilla
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Pharmacogenet Genomics 15:393-8. 2005
    ..To determine if the lower activity Met allele of COMT was associated with smoking cessation in women, we used two independent studies: a population-based case--control study and a nicotine replacement clinical trial...
  58. ncbi request reprint Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R)
    Enkhtsetseg Purev
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    J Immunol 173:6472-80. 2004
    ....
  59. pmc Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
    Lin Zhang
    Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 105:7004-9. 2008
    ..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer...
  60. ncbi request reprint Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample
    James C Coyne
    Departments of Psychiatry and Hematology Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Gen Hosp Psychiatry 26:121-8. 2004
    ..The low rate of untreated psychiatric morbidity may signal a need for multisite collaborations to generate adequate numbers of participants in clinical trials...
  61. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  62. ncbi request reprint In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort"
    Angela DeMichele
    J Clin Oncol 25:5675-7. 2007
  63. ncbi request reprint Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients
    Karen Smith
    Department of Oncology Hematology, Memorial Sloan Kettering Cancer Center, USA
    Clin Breast Cancer 6:260-6; discussion 267-9. 2005
    ....
  64. ncbi request reprint Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations
    Lois B Travis
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 98:15-25. 2006
    ..These research areas warrant high priority to promote NCI's goal of eliminating pain and suffering related to cancer...
  65. ncbi request reprint Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posed
    Angela DeMichele
    J Clin Oncol 20:1164-6. 2002